An update on treatment and prevention strategies for Alzheimer's disease

被引：36

作者：

Neugroschl, Judith ^{[1
]}

Sano, Mary ^{[1
]}

机构：

[1] James J Peters Vet Affairs Med Ctr, Bronx, NY 10468 USA

来源：

CURRENT NEUROLOGY AND NEUROSCIENCE REPORTS | 2009年 / 9卷 / 05期

关键词：

RANDOMIZED CONTROLLED-TRIAL; HEALTH INITIATIVE MEMORY; MILD COGNITIVE IMPAIRMENT; CONJUGATED EQUINE ESTROGENS; AMYLOID PRECURSOR PROTEIN; TOTAL HOMOCYSTEINE LEVELS; DOUBLE-BLIND TRIAL; POSTMENOPAUSAL WOMEN; A-BETA; PLUS PROGESTIN;

D O I：

10.1007/s11910-009-0054-1

中图分类号：

R74 [神经病学与精神病学];

学科分类号：

100204 [神经病学];

摘要：

With the aging of the population, the incidence and prevalence of Alzheimer's disease will grow, increasing the burden on individuals and society. While ameliorating symptoms, the currently available treatments approved by the US Food and Drug Administration do not halt progression or cure the illness. This article discusses recent data on treatment strategies targeting amyloid and tau pathology. Novel therapeutic strategies such as inhibitors of receptors for advanced glycation end products (RAGE), potential mitochondrial modification with Dimebon, anti-inflammatory approaches, and cholesterol-lowering agents are also reviewed. An update on results from pharmacologic and nonpharmacologic prevention trials is provided.

引用

页码：368 / 376

页数：9

共 72 条

[1]

High-dose B vitamin supplementation and cognitive decline in Alzheimer disease - A randomized controlled trial [J].

Aisen, Paul S. ;

Schneider, Lon S. ;

Sano, Mary ;

Diaz-Arrastia, Ramon ;

van Dyck, Christopher H. ;

Weiner, Myron F. ;

Bottiglieri, Teodoro ;

Jin, Shelia ;

Stokes, Karen T. ;

Thomas, Ronald G. ;

Thal, Leon J. .

JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 2008, 300 (15) :1774-1783

[2]

The inflammatory hypothesis of Alzheimer disease: Dead or alive? [J].

Aisen, Paul S. .

ALZHEIMER DISEASE & ASSOCIATED DISORDERS, 2008, 22 (01) :4-5

[3]

Effects of rofecoxib or naproxen vs placebo on Alzheimer disease progression - A randomized controlled trial [J].

Aisen, PS ;

Schafer, KA ;

Grundman, M ;

Pfeiffer, E ;

Sano, M ;

Davis, KL ;

Farlow, MR ;

Jin, S ;

Thomas, RG ;

Thal, LJ .

JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 2003, 289 (21) :2819-2826

[4]

A randomized controlled trial of prednisone in Alzheimer's disease [J].

Aisen, PS ;

Davis, KL ;

Berg, JD ;

Schafer, K ;

Campbell, K ;

Thomas, RG ;

Weiner, MF ;

Farlow, MR ;

Sano, M ;

Grundman, M ;

Thal, LJ .

NEUROLOGY, 2000, 54 (03) :588-593

[5]

*ALZH RES FOR, PRX03140 ALZH RES FO

[6]

*ALZH RES FOR, OUT BLUE TAU BAS TRE

[7]

A novel immunotherapy for Alzheimer's disease: Antibodies against the p-secretase cleavage site of APP [J].

Arbel, Michal ;

Solomon, Beka .

CURRENT ALZHEIMER RESEARCH, 2007, 4 (04) :437-445

[8]

Methylene blue delays cellular senescence and enhances key mitochondrial biochemical pathways [J].

Atamna, Hani ;

Nguyen, Andy ;

Schultz, Carla ;

Boyle, Kathleen ;

Newberry, Justin ;

Kato, Hiroyuki ;

Ames, Bruce N. .

FASEB JOURNAL, 2008, 22 (03) :703-712

[9]

Mitochondria as a target for neurotoxins and neuroprotective agents [J].

Bachurin, SO ;

Shevtsova, EP ;

Kireeva, EG ;

Oxenkrug, GF ;

Sablin, SO .

NEUROPROTECTIVE AGENTS, 2003, 993 :334-344

[10]

Therapeutic strategies for Alzheimer's disease [J].

Barten, Donna M. ;

Albright, Charles F. .

MOLECULAR NEUROBIOLOGY, 2008, 37 (2-3) :171-186

← 1 2 3 4 5 6 7 8 →